NCT00000810View on ClinicalTrials.gov

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 1996

Conditions
HIV Infections
Interventions
DRUG

Delavirdine mesylate

DRUG

Zidovudine

DRUG

Didanosine

Trial Locations (10)

14642

Univ. of Rochester ACTG CRS, Rochester

20059

Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington D.C.

60611

Northwestern University CRS, Chicago

80262

University of Colorado Hospital CRS, Aurora

331361013

Univ. of Miami AIDS CRS, Miami

943055107

Stanford CRS, Stanford

Unknown

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

Unc Aids Crs, Chapel Hill

The Ohio State Univ. AIDS CRS, Columbus

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000810 - Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S) | Biotech Hunter | Biotech Hunter